Q-omics provides the consensus-scored INPP5B profile across patient tissues and cancer cell-line models. INPP5B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, INPP5B is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, INPP5B RNA expression shows 20,008 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, and ACC as cancer lineages where INPP5B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INPP5B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INPP5B survival associations across molecular data types. INPP5B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INPP5B RNA expression–survival associations across cancer types. High INPP5B expression shows unfavorable associations in ACC, KICH and LGG, but favorable associations in LUAD, HNSC and SCLC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for INPP5B RNA expression.
This table summarizes INPP5B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for INPP5B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INPP5B shows lower tumor expression in LUAD, KICH, BRCA, BLCA and LUSC and higher tumor expression in HNSC. The LUAD box plot shows higher INPP5B RNA expression in normal versus tumor tissue (log2 FC = −0.718, t-test p < 0.001).
This table shows molecular features associated with INPP5B in patient tissues and cancer cell lines. In patient samples, INPP5B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, INPP5B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and PANCREAS.
